Journal of Medicinal Chemistry · 2011 · 36 citations · 18 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationCannabinoid PharmacologyHit-to-lead OptimizationLipophilicity OptimizationPharmacokinetic OptimizationPotency OptimizationReceptor PharmacologyCannabinoid AgonistsCannabinoid Receptor PharmacokineticsCannabinoid Receptor PharmacologyCannabinoid Structure-activity RelationshipsOptimization Of Pharmacodynamic PropertiesOral Bioavailability OptimizationOral Drug BioavailabilityPhysicochemical Properties
Here, we report the identification and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel chemotype with selective cannabinoid CB2 receptor agonist activity. 1 is a potent and selective cannabinoid CB2 receptor agonist (hCB2 pEC(50) = 8.6). The compound was found to be metabolically unstable, which resulted in low oral bioavailability in rat (F(po) = 4%) and possessed off-target activity at the hERG ion channel (pK(i) = 5.5). Systematic modification of physicochemical properties, such as lipophilicity and basicity, was used to optimize the pharmacokinetic profile and hERG affinity of this novel class of cannabinoid CB2 receptor agonists. This led to the identification of 44 as a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist (hCB2 pEC(50) = 8.0; hERG pK(i) < 4; F(po) = 100%), which was active in a rat spinal nerve ligation model of neuropathic pain.
18
Peripheral cannabinoid receptor, CB2, regulates bone mass
Orr Ofek, Meliha Karsak, Nathalie Leclerc et al. · Proceedings of the National Academy of Sciences · 2006 · 531 citations · Full text
Cannabis: pharmacology and toxicology in animals and humans
Irma B. Adams, Billy R. Martin · Addiction · 1996 · 503 citations
Pharmacy, Pharmacology, Toxicology +10
CB2 cannabinoid receptor-mediated peripheral antinociception
Philip T. Malan, Mohab Ibrahim, Hongfeng Deng et al. · Pain · 2001 · 389 citations
Medicine, Neuroscience, Pharmacology +14